Association of Pregnancy With the Onset of Clinically Isolated Syndrome
Nguyen, A.-L., Vodehnalova, K., Kalincik, T., Signori, A., Havrdova, E.K., Lechner-Scott, J., Skibina, O.G., Eastaugh, A., Taylor, L., Baker, J., et al. (2020). JAMA Neurol (77). p.1496–1503

Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score
Lefort, M., Foucher, Y., Lenain, R., Vukusic, S., Edan, G., and Leray, E. (2020). Pharmacoepidemiol Drug Saf (29). p.1680–1688

Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI
Roca, P., Attye, A., Colas, L., Tucholka, A., Rubini, P., Cackowski, S., Ding, J., Budzik, J.-F., Renard, F., Doyle, S., et al. (2020). Diagn Interv Imaging (101). p.795–802

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor
Vukusic, S., Durand-Dubief, F., and Marignier, R. (2020a). Mult Scler (26). p.1610–1611

Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Trojano, M., Patti, F., Izquierdo, G., et al. (2020a). Brain (143). p.2742–2756

Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Trojano, M., Patti, F., Izquierdo, G., et al. (2020b). Brain (143). p.2742–2756

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Maarouf, A., Rico, A., Boutiere, C., Perriguey, M., Demortiere, S., Pelletier, J., Audoin, B., and Under the aegis of OFSEP (2020). Neurol Neuroimmunol Neuroinflamm (7). p.e825

Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event
Lebrun-Frenay, C., Kantarci, O., Siva, A., Sormani, M.P., Pelletier, D., Okuda, D.T., and 10-year RISC study group on behalf of SFSEP, OFSEP (2020). Ann Neurol (88). p.407–417

Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort
Branger, P., Parienti, J.-J., Derache, N., Kassis, N., Assouad, R., Maillart, E., and Defer, G. (2020). Neurotherapeutics (17). p.989–993

Facteurs pronostiques de la première attaque dans des maladies du spectre de la neuromyélite optique et associées à l’anticorps anti-MOG
Guillaume, M. (2020). p.146

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment
Ouallet, J.-C. (2020). Rev Neurol (Paris) (176). p.500–504

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes
de Seze, J., and Bigaut, K. (2020). Rev Neurol (Paris) (176). p.497–499

Reader response: Evaluation of efficacy and tolerability of first-line therapies in NMOSD
Leite, M.I. (2020).

Author response: Evaluation of efficacy and tolerability of first-line therapies in NMOSD
Zephir, H., Poupart, J., Deschamps, R., Audoin, B., Ciron, J., Maillart, E., Papeix, C., Collongues, N., Bourre, B., Cohen, M., et al. (2020).

Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients
Calocer, F., Dejardin, O., Kwiatkowski, A., Bourre, B., Vermersch, P., Hautecoeur, P., Launoy, G., and Defer, G. (2020). Mult Scler Relat Disord (40). p.101930

Predictive medicine in multiple sclerosis: A systematic review
Havas, J., Leray, E., Rollot, F., Casey, R., Michel, L., Lejeune, F., Wiertlewski, S., Laplaud, D., and Foucher, Y. (2020). Mult Scler Relat Disord (40). p.101928

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
Maillart, E., Durand-Dubief, F., Louapre, C., Audoin, B., Bourre, B., Derache, N., Ciron, J., Collongues, N., de Sèze, J., Cohen, M., et al. (2020). J Neuroinflammation (17). p.128

MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No
Cobo-Calvo, A., and Marignier, R. (2020). Mult. Scler. (26). p.274–276

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study
Cobo-Calvo, Á., d’Indy, H., Ruiz, A., Collongues, N., Kremer, L., Durand-Dubief, F., Rollot, F., Casey, R., Vukusic, S., De Seze, J., et al. (2020). Neurol Neuroimmunol Neuroinflamm (7).

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions
Brisset, J.-C., Kremer, S., Hannoun, S., Bonneville, F., Durand-Dubief, F., Tourdias, T., Barillot, C., Guttmann, C., Vukusic, S., Dousset, V., et al. (2020). J Neuroradiol

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France
Vukusic, S., Rollot, F., Casey, R., Pique, J., Marignier, R., Mathey, G., Edan, G., Brassat, D., Ruet, A., De Sèze, J., et al. (2020b). JAMA Neurol (77). p.94–102

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France
Vukusic, S., Casey, R., Rollot, F., Brochet, B., Pelletier, J., Laplaud, D.-A., De Sèze, J., Cotton, F., Moreau, T., Stankoff, B., et al. (2020c). Mult Scler (26). p.118–122

Longitudinal study of functional brain network reorganization in clinically isolated syndrome
Koubiyr, I., Deloire, M., Besson, P., Coupé, P., Dulau, C., Pelletier, J., Tourdias, T., Audoin, B., Brochet, B., Ranjeva, J.-P., et al. (2020). Mult. Scler. (26). p.188–200

Evaluation of efficacy and tolerability of first-line therapies in NMOSD
Poupart, J., Giovannelli, J., Deschamps, R., Audoin, B., Ciron, J., Maillart, E., Papeix, C., Collongues, N., Bourre, B., Cohen, M., et al. (2020). Neurology (94). p.e1645–e1656

NEUROLOGY MS ID#: NEUROLOGY/2020/080531 MS TITLE: Outcome predictors of the first attack in Neuromyelitis Optica Spectrum Disorders and MOG-Associated Disease
Collongues, N.